Phase II trial of induction therapy with EPOCH chemotherapy [etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin] and maintenance therapy with combivir/interferon alpha-2a for HTLV [human T-cell leukaemia virus type 1]-associated T-cell non-Hodgkin's lymphoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Antineoplastics; Cyclophosphamide; Doxorubicin; Etoposide; Interferon alpha; Lamivudine; Prednisone; Vincristine; Zidovudine
- Indications HTLV-I infections; Leukaemia; Lymphoma
- Focus Adverse reactions; Therapeutic Use
- 03 Feb 2016 Biomarkers information updated
- 10 Aug 2008 Status changed from in progress to completed according to clinicaltrials.gov record.
- 10 Aug 2008 The actual completion date for this trial is now 1 Aug 2008 according to clinicaltrials.gov record.